U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
HISTONE-LYSINE N-METHYLTRANSFERASE EZH2
J2234208AE
Other
General
Record Details
Names
6
Identifiers
7
Subunits
1
Glycosylation
1
Relationships
4
Modifications
4
Characteristic Attributes
1
HISTONE-LYSINE N-METHYLTRANSFERASE EZH2
J2234208AE
Other
General
Approval Year
Unknown
149,124
Record Details
Substance Class
Protein
Protein Sub Type
Sequence Type
COMPLETE
Record UNII
J2234208AE
Record Status
Validated (UNII)
Record Version
12
11
10
9
8
7
6
5
4
3
2
1
Names
6
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
ENHANCER OF ZESTE 2 (HUMAN CELL LINE BJA-B GENE EZH2)
Preferred Name
English
HISTONE-LYSINE N-METHYLTRANSFERASE EZH2
Common Name
English
LYSINE N-METHYLTRANSFERASE 6
Common Name
English
ENHANCER OF ZESTE HOMOLOG 2
Common Name
English
ENX-1
Common Name
English
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Identifiers
7
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
WIKIPEDIA
EZH2
PRIMARY
CAS
459578-94-0
PRIMARY
UNIPROT
Q15910
PRIMARY
FDA UNII
J2234208AE
PRIMARY
PHAROS
Q15910
PRIMARY
Showing 1 to 5 of 7 entries
Previous
1
2
Next
Subunits
1
Glycosylation
1
Glycosylation Type
HUMAN
Show
5
20
100
All
entries
Glycosylation Link Type
Site
Glycosylation Link Type
Site
O
1_75
Showing 1 to 1 of 1 entries
Previous
1
Next
Relationships
4
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
Q40W93WPE1
TAZEMETOSTAT
INHIBITOR -> TARGET
Comments:
biochemical assay
Qualification:
IC50
Amount:
4 NANOMOLAR (average)
455J2479FY
LIRAMETOSTAT
INHIBITOR -> TARGET
S4L4MM20B6
Mevrometostat
INHIBITOR -> TARGET
Qualification:
Ki
Amount:
[<0.1] NANOMOLAR (average)
W4OGW9QZ97
GSK-2816126
INHIBITOR -> TARGET
Comments:
The maximal dose and schedule attained with GSK2816126 has shown insufficient evidence of clinical activity, and does not justify further clinical investigation.
Showing 1 to 4 of 4 entries
Previous
1
Next
Modifications
4
Structural Modifications
Show
5
20
100
All
entries
Modification Type
Location Site
Location Type
Residue Modified
Extent
Fragment Name
Fragment Approval
Modification Type
Location Site
Location Type
Residue Modified
Extent
Fragment Name
Fragment Approval
AMINO ACID SUBSTITUTION
[1_345]
THREONINE
THREONINE PHOSPHATE
3L4WX7B1EI
AMINO ACID SUBSTITUTION
[1_339] [1_367] [1_487]
THREONINE
THREONINE PHOSPHATE
3L4WX7B1EI
AMINO ACID SUBSTITUTION
[1_76] [1_363] [1_366]
SERINE
DEXFOSFOSERINE
VI4F0K069V
AMINO ACID SUBSTITUTION
[1_21]
SERINE
DEXFOSFOSERINE
VI4F0K069V
Showing 1 to 4 of 4 entries
Previous
1
Next
Characteristic Attributes
1
Show
5
20
100
All
entries
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED)
CHEMICAL
NUMBER AVERAGE 85363 DA (average)
UNMODIFIED MW
Showing 1 to 1 of 1 entries
Previous
1
Next
